Background: Antiviral effect of remdesivir against SARS-CoV-2 is still controversial, during the COVID-19 pandemic, using antiviral drugs may be an efficient strategy as there is no proven effective treatment. Remdesivir was approved as a promising antiviral drug for the pandemic COVID-19 disease. There is a debate over its efficacy, with different studies considering various factors.
Objective: The aim of the study was to evaluate the clinical outcome of using Remdesivir in elderly patients with severe and critically ill COVID-19 infection who received standard-of-care treatment and Remdesivir in comparison to similar patients who have received standard-of-care treatment only.
Methods: This is a retrospective observational study of 330 cases admitted to Geriatrics Isolation Hospital at Ain Shams University classified into 2 groups, Group A: 165 patients received standard-of-care treatment plus Remdesivir, Group B:165 patients received standard-of-care treatment only. Data extracted included the patient's medical history and oxygen demand on admission and on discharge. Laboratory investigations include C reactive protein, ferritin, complete blood count, kidney function test, and liver function test on admission and on discharge. The outcome was reported as regards length of hospital stay, morbidity and mortality.
Results: results showed that the percentage of mortality in cases who received remdesivir was 17.2% and who didn't receive it was 44.9%, In-hospital mortality was less in cases who received remdesivir with a significant difference statistically (P value<0.001).
Conclusion: Remdesivir plus standard-of-care treatment for severe and critically ill cases improves prognosis in comparison to standard-of-care treatment only.